Legend Biotech stock gained 1.10 percent on October 5

Legend Biotech (ISIN US52490G1022) closed at USD 18.78 on Nasdaq on October 5, 2026, gaining 1.10 percent from the prior close of USD 18.57. The latest company catalyst is long-term CARVYKTI evidence: on September 25, 2026, Legend Biotech reported five-year follow-up results from the CARTITUDE-2 Cohort A study.

Five-year data strengthen CARVYKTI case

Ten of 20 patients, or 50 percent, remained alive and progression-free at least five years after a single infusion without maintenance therapy. The study showed a median progression-free survival of 60.5 months and a five-year overall survival rate of 69.2 percent, according to Legend Biotech.

The evidence matters because CARVYKTI is the companys lead commercial therapy and is developed with Johnson and Johnson. The small cohort size of 20 patients places the percentages in a specific clinical context, while the 60.7-month median follow-up gives the durability data a longer horizon.

Revenue growth meets analyst caution

Legend Biotech reported second-quarter 2026 revenue of USD 387.5 million and EPS of USD 0.09 on August 11, 2026. Revenue was up 51.9 percent year over year and exceeded the USD 355.96 million consensus estimate, while EPS topped the USD 0.07 estimate, according to MarketBeat.

MarketBeat reported a Hold consensus from 15 analysts, including eight Buys, six Holds and one Sell, with an average 12-month price target of USD 53.14. At the October 5 closing price, the stock lay 64.66 percent below that average target, a gap that reflects both the growth opportunity and the market skepticism surrounding biotechnology execution.

H.C. Wainwright reiterated a Buy rating and a USD 65 price target on September 30, 2026, after reviewing the durability data, Investing.com reported. The unchanged target contrasts with the broader Hold consensus and shows how analysts weigh clinical durability against profitability and execution risks.

Stock remains below yearly high

At USD 18.78 on October 5, 2026, Legend Biotech stock stood 49.92 percent below its Nasdaq 52-week high of USD 37.50 and USD 2.54 above its 52-week low of USD 16.24. The session volume was 1,763,069 shares, and market capitalization was USD 3.7 billion.

Yahoo Finance lists November 11, 2026, as the next earnings date for Legend Biotech, Yahoo Finance reports. That date gives the next results update a clear checkpoint after the latest clinical and commercial evidence.

Legend Biotech stock at October close

Legend Biotech stock closed at USD 18.78 on Nasdaq on October 5, 2026, with a 1.10 percent daily gain and a 52-week range of USD 16.24 to USD 37.50.

Upcoming dates for Legend Biotech stock

• November 11, 2026: Quarterly earnings date

More news and analyses on Legend Biotech stock